Guardant Health’s Q3 Revenue Jumps 39% to $281M, Sparks Acquisition-Fueled Rally
Guardant Health’s Q3 earnings beat expectations on volume-driven revenue of $281 million, a 39% year-on-year increase, and news of a competitor acquisition. This performance helped drive its market capitalization to $12.37 billion as shares rallied on stronger industry momentum.
1. Q3 Revenue and Volume Growth
Guardant Health delivered Q3 revenue of $281 million, a 39% year-on-year increase, driven by robust growth in its liquid biopsy test volumes. The company also announced the strategic acquisition of a competitor, reinforcing its market position and expanding its testing capabilities.
2. Fund Contribution and Share Reaction
The strong earnings surprise and acquisition news positioned Guardant Health as a leading contributor to a major growth equity fund’s Q4 performance, resulting in a notable uptick in its share price. Industry sentiment has improved as business momentum in precision oncology accelerates.
3. Market Capitalization and Hedge Fund Activity
Following these developments, Guardant Health’s market capitalization rose to $12.37 billion, with shares closing at approximately $95.27. Hedge fund holdings increased to 62 portfolios, up from 50 in the prior quarter, indicating growing institutional interest.